27/02/2013

ESTEVE RATED ’EXCELLENT’ FOR ITS R&D ACTIVITIES

Awarded by Profarma, the official seal of quality of the Ministry of Industry that fosters research and competitiveness in the pharmaceutical sector.

One more year -uninterruptedly so for the 27 years of history of the Profarma Plan-, ESTEVE has been awarded the highest qualification for its research, development and innovation (R&D&i) activities.

Specifically, ESTEVE comes under Group A of the Profarma Plan (2009-2012), composed of innovative pharmaceutical companies that carry out truly significant research activities and have their own production plant or R&D center.

The Profarma Plan is a joint initiative of the Industry, Energy and Tourism, Health, Social Services and Equality, Economy and Competitiveness, Ministries. It is designed to favor the sector's modernization and provide added value with activities such as R&D. These activities are rated as 'Fair', 'Good', 'Very Good' or 'Excellent' according to scientific, economic and industrial standards.

From the very beginning, back in 1929, innovation has been ESTEVE's hallmark and the key to its growth. ESTEVE presently offers a portfolio of highly innovative projects designed to provide solutions to unmet medical needs likely to have a significant impact on society. Special emphasis is placed on analgesia, where two projects in clinical phase stand out for the treatment of moderate to severe chronic pain and neuropathic pain, respectively.

ESTEVE is involved in HIVACAT, a research program devoted to developing an AIDS vaccine. HIVACAT is a public private consortium that joins the efforts of ESTEVE, the Hospital Clínic of Barcelona and the Hospital Germans Trias i Pujol of Badalona, as well as the additional support from the 'La Caixa' foundation and the Catalan Government (Generalitat de Catalunya). Also worth mentioning is the project now conducted jointly with the Center for Animal Biotechnology and Gene Therapy (CBATEG) of the Autonomous University of Barcelona for the development of gene therapy to treat the Sanfilippo syndrome Type A, a rare but devastating childhood disease. All these projects have been supported by the Spanish Ministry of Economy and Competitiveness.

At the European level, ESTEVE takes part in four projects IMI (Innovative Medicines Initiative, driven by the European Federation of Pharmaceutical Industries and Associations, EFPIA, and the European Union), such as EUROPAIN, focusing on chronic pain research, and where ESTEVE is the only Spanish pharmaceutical company involved in the program.


For more information www.esteve.com/research-development

You can follow ESTEVE on Twitter at: twitter.com/esteve_news.

Related Information

Last news

  • ESTEVE APPOINTS JORDI MUNTAÑOLA AS CHIEF COMMERCIAL OFFICER FOR EUROPE

    Jordi Muntañola will take on the leadership of all the pharmaceutical activities in Spain and Europe

    read more
  • POMPEU FABRA UNIVERSITY AND ESTEVE ARE TO INVESTIGATE NEW TARGETS FOR TREATING NEUROPATHIC PAIN

    The RIBOPAIN project aims to identify new therapeutic solutions for pain and to develop more effective drugs

    read more
  • ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY

    Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spain

    read more

Follow us at

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.